User profiles for Patrick B Ryan

Patrick Ryan

Janssen Research and Development
Verified email at cornell.edu
Cited by 13315

[HTML][HTML] Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers

…, YC Li, PE Stang, D Madigan, PB Ryan - Studies in health …, 2015 - ncbi.nlm.nih.gov
The vision of creating accessible, reliable clinical evidence by accessing the clinical
experience of hundreds of millions of patients across the globe is a reality. The Observational …

Validation of a common data model for active safety surveillance research

JM Overhage, PB Ryan, CG Reich… - Journal of the …, 2012 - academic.oup.com
Objective Systematic analysis of observational medical databases for active safety surveillance
is hindered by the variation in data models and coding systems. Data analysts often find …

Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership

PE Stang, PB Ryan, JA Racoosin… - Annals of internal …, 2010 - acpjournals.org
The US Food and Drug Administration (FDA) Amendments Act of 2007 mandated that the
FDA develop a system for using automated health care data to identify risks of marketed drugs …

Characterizing treatment pathways at scale using the OHDSI network

G Hripcsak, PB Ryan, JD Duke… - Proceedings of the …, 2016 - National Acad Sciences
Observational research promises to complement experimental research by providing large,
diverse populations that would be infeasible for an experiment. Observational research can …

Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis

…, CG Reich, J Duke, D Madigan, G Hripcsak, PB Ryan - The Lancet, 2019 - thelancet.com
Background Uncertainty remains about the optimal monotherapy for hypertension, with current
guidelines recommending any primary agent among the first-line drug classes thiazide or …

Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study

…, PR Rijnbeek, T Duarte-Salles, MA Suchard, PB Ryan… - bmj, 2021 - bmj.com
Objective To quantify the background incidence rates of 15 prespecified adverse events of
special interest (AESIs) associated with covid-19 vaccines. Design Multinational network …

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with …

PB Ryan, JB Buse, MJ Schuemie… - Diabetes, Obesity …, 2018 - Wiley Online Library
Aims Sodium glucose co‐transporter 2 inhibitors (SGLT2i) are indicated for treatment of type
2 diabetes mellitus (T2DM); some SGLT2i have reported cardiovascular benefit, and some …

Feasibility and utility of applications of the common data model to multiple, disparate observational health databases

…, FJ DeFalco, A Londhe, V Zhu, PB Ryan - Journal of the …, 2015 - academic.oup.com
Patrick B Ryan Patrick B Ryan … Erica A Voss, Rupa Makadia, Amy Matcho, Qianli Ma,
Chris Knoll, Martijn Schuemie, Frank J DeFalco, Ajit Londhe, Vivienne Zhu, Patrick B Ryan, …

Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention

…, D Madigan, G Hripcsak, A Gupta, CG Reich, PB Ryan… - Jama, 2020 - jamanetwork.com
Importance Current guidelines recommend ticagrelor as the preferred P2Y12 platelet
inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large …

[HTML][HTML] Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis

…, HM Krumholz, D Prieto-Alhambra, PB Ryan… - The Lancet Digital …, 2021 - thelancet.com
Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) have been postulated to affect susceptibility to COVID-19. Observational …